Data gathered: May 30
Alternative Data for Revolution Medicines
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 52 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 38,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 814 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 629 | Sign up | Sign up | Sign up |
| NPS | 36 | Sign up | Sign up | Sign up |
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
| Price | $38.66 |
| Target Price | Sign up |
| Volume | 443,920 |
| Market Cap | $7.03B |
| Year Range | $31.13 - $60.6 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Financial Contrast: Revolution Medicines (NASDAQ:RVMD) & Fate Therapeutics (NASDAQ:FATE)May 27 - ETF Daily News |
|
Q2 EPS Forecast for Revolution Medicines Lowered by AnalystMay 17 - ETF Daily News |
 |
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trialMay 14 - Yahoo |
|
Fennec Pharmaceuticals (NASDAQ:FENC) and Revolution Medicines (NASDAQ:RVMD) Financial SurveyMay 13 - ETF Daily News |
|
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung CancerMay 13 - Yahoo |
|
Q2 EPS Forecast for Revolution Medicines Cut by AnalystMay 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -213M | -237M | -1.130 |
| Q4 '24 | 262M | 131M | 131M | -195M | -213M | -1.120 |
| Q3 '24 | 0 | 0 | 0 | -156M | -176M | -0.940 |
| Q2 '24 | 0 | 13M | -13M | -133M | -155M | -0.810 |
| Q1 '24 | 0 | 118M | -118M | -116M | -139M | -0.700 |
Insider Transactions View All
| Cislini Jeff filed to sell 57,723 shares at $38.7. March 24 '25 |
| Kelsey Stephen Michael filed to sell 293,051 shares at $39. March 19 '25 |
| Horn Margaret A filed to sell 153,533 shares at $39. March 19 '25 |
| Anders Jack filed to sell 115,006 shares at $39. March 19 '25 |
| Cislini Jeff filed to sell 59,764 shares at $39. March 19 '25 |
Similar companies
Read more about Revolution Medicines (RVMD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Revolution Medicines?
The Market Cap of Revolution Medicines is $7.03B.
What is the current stock price of Revolution Medicines?
Currently, the price of one share of Revolution Medicines stock is $38.66.
How can I analyze the RVMD stock price chart for investment decisions?
The RVMD stock price chart above provides a comprehensive visual representation of Revolution Medicines' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Revolution Medicines shares. Our platform offers an up-to-date RVMD stock price chart, along with technical data analysis and alternative data insights.
Does RVMD offer dividends to its shareholders?
As of our latest update, Revolution Medicines (RVMD) does not offer dividends to its shareholders. Investors interested in Revolution Medicines should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Revolution Medicines?
Some of the similar stocks of Revolution Medicines are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.